Chinese pharmaceutical company Guiyang Xintian Pharmaceutical has announced the pricing for its proposed initial public offering (IPO) of shares to raise ¥317.02m ($46m) in gross proceeds.

Under the IPO, the company will issue 17.22 million shares priced at ¥18.41 ($2.67) each.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

US-based biopharmaceutical company TetraGenetics has announced that it has secured venture funding from JDRF T1D Fund in order to expedite the development of a type 1 diabetes immunotherapy.

Magenta Therapeutics has completed a series B financing round to raise $50m, which will be utilised to develop product candidates in transplantation medicines used for a more precise preparation of patients, as well as stem cell harvesting and expansion.

Magenta Therapeutics is a biotechnology company based in the US.

See Also:

"US-based biopharmaceutical company TetraGenetics has announced that it has secured venture funding from JDRF T1D Fund in order to expedite the development of a type 1 diabetes immunotherapy."

ImCheck Therapeutics has raised €20m ($21.8m) in a series A venture financing round led by Boehringer Ingelheim Venture Fund (BIVF), Kurma Partners and Idinvest Partners, and participated in by Gimv NV and Life Sciences Partners.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Based in France, ImCheck Therapeutics develops biotherapies for immune-oncology.

The proceeds from the venture financing round are intended to be used to advance the development of a number of drug candidates and begin clinical trials by 2018.

US-based pulmonary drug developer Savara intends to raise $18m in gross proceeds through a public offering of shares.

The proceeds are intended to be used for working capital and general corporate purposes.